Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity Natural killer (NK) cells have a key role in the host defense against pathogens, as well as malignant cells. 1 They mediate both natural and antibody-dependent cell-mediated cytotoxicity (ADCC), and produce a variety of immunoregulatory cytokines, enhancing innate and adaptive immune responses. Their cytotoxic functions are strictly regulated by a complex interplay between stimulatory and inhibitory receptors, enabling the NK cells to discriminate between healthy and abnormal cells. The stimulatory receptor NK group 2 member D (NKG2D), which is constitutively expressed by all-resting NK cells, and its n Statistically significant differences compared with controls without added sensitizing proteins (Po0.05).
Letters to the Editor corresponding ligands have major functions in both antipathogen and anti-cancer immune responses. NKG2D is a homodimeric type II transmembrane protein belonging to the family of C-type lectin-like receptors.
1,2 Engagement of NKG2D induces perforin and granzyme-mediated killing mechanisms, as well as the secretion of cytokines. Human ligands for NKG2D are cell-surface glycoproteins comprising two major histocompatibility complex class-I chain-related proteins (MIC) and several unique long-16 binding proteins (ULBP), which are rarely expressed on healthy tissues, but frequently become upregulated upon cell stress such as infection with a pathogen or malignant transformation, and serve as alert signals for recognition and elimination of aberrant cells. 3 Therefore, utilizing the NKG2D signaling pathway to elicit NK cell-based anti-tumor responses may be a promising strategy. Recently, a bifunctional fusion protein consisting of a tumor cell-directed CD138 singlechain fragment variable and the NKG2D-specific ligand ULBP2 has been reported. This fusion protein efficiently sensitized multiple myeloma cells for NK cell-mediated lysis. 4 In the current study, two novel bifunctional antibody-based proteins consisting of different NKG2D ligands and a human CD20 single-chain fragment variable were designed. The extracellular domains of MICA or ULBP2 were genetically fused to the human CD20 single-chain fragment variable derived from mAb 7D8 (Figure 1a ; further information is provided in the Supplementary Material and Methods section). The resulting fully human fusion proteins MICA:7D8 and ULBP2:7D8 were expressed in mammalian cells, and purified by affinity chromatography. Integrity and purity of the recombinant proteins were confirmed by SDS-polyacrylamide gel Letters to the Editor electrophoresis and western transfer experiments (data not shown). Gel filtration revealed that both MICA:7D8 and ULBP2:7D8 pre-dominantly formed monomers (data not shown). MICA:7D8 and ULBP2:7D8 had bispecific binding properties, because both molecules were able to bind to CD20-positive Ramos cells and to simultaneously react with the NKG2D receptor (Figure 1b) . No binding to cells negative for CD20 or NKG2D expression was observed (data not shown).
The cytotoxic activities of MICA:7D8 and ULBP2:7D8 were investigated by chromium release assays using human mononuclear cells (MNC) from healthy donors as effector cells. Both agents triggered significant lysis of CD20-expressing Raji cells ( Figure 1c) . As expected, none of the control proteins, MICA:TH69 and ULBP2:TH69 containing a functional arm directed against CD7, triggered killing of B-lymphoid tumor cells. No lysis was induced by the bifunctional proteins in absence of MNC, indicating that antigen-restricted cellmediated cytotoxicity was the underlying killing mechanism (Figure 1c) . Because cytotoxic T cells, which were also contained in the MNC fraction express cell surface NKG2D, 2, 3 attempts were made to define the relevant effector cell population. The activation status of NK and T cells as revealed by expression of the early-inducible activation marker CD69 was investigated after co-incubation of MNC with Raji cells in the presence of MICA:7D8 or ULBP2:7D8 by flow cytometry (Figure 1d ). CD69 upregulation was observed for NK cells, but not for T cells, suggesting NK cells to be the relevant effector population. In good agreement, purified NK cells from healthy donors were triggered in the presence of MICA:7D8 and ULBP2:7D8 to lyse the CD20-positive lymphoma cell lines Raji, Ramos and Daudi (Figure 2a) . Although both molecules mediated cellular cytotoxicity in a dose-dependent manner at nanomolar concentrations, ULBP2:7D8 triggered stronger cellular cytotoxicity than MICA:7D8 with respect to the maximum lysis achieved. More detailed studies indicated that target cells died by apoptosis as demonstrated by caspase cleavage assays and flow cytometry (Supplementary Figure 1) . The antigen-specific modes of action exerted by MICA:7D8 and ULBP2:7D8 were Letters to the Editor confirmed, because CD20-negative CEM cells remained unaffected by these agents (Supplementary Figure 2A) , and in blocking experiments, cytotoxic activities of both proteins were specifically inhibited by addition of molar excess of a 7D8 Fab fragment or an NKG2D-specific antibody (Supplementary Figure 2B) . To analyze the ability of MICA:7D8 and ULBP2:7D8 to sensitize freshly isolated tumor cells for NK cell-mediated lysis (Figures 2b -d) , tumor cells were enriched from patients diagnosed with chronic lymphocytic leukemia, mantle cell lymphoma or marginal zone lymphoma (Supplementary Table  1 ). Expression levels of endogenous MIC and ULBP2 molecules were consistently low or not detectable (Supplementary Figure  3) . Using NK cells from different healthy donors as effector cells, MICA:7D8 and ULBP2:7D8 mediated lysis of primary tumor cells. Antigen-specificity again was verified, because neither MICA:TH69 nor ULBP2:TH69 had significant effects (Figures 2c  and d) . Analysis of CD20 expression suggested that increasing expression levels favored the susceptibility to lysis induced by MICA:7D8 and ULBP2:7D8 (Supplementary Figure 4) . Additionally, the ability of ULBP2:7D8 to activate patient-derived NK cells to lyse autologous tumor cells from the same patients was investigated (Figure 2e ). Although the extent of lysis was lower in experiments performed in autologous than in allogeneic settings, ULBP2:7D8 also had measurable cytotoxic effects under these stringent conditions.
Clinical observations and animal models revealed that engagement of Fc receptors is important for the efficacy of therapeutic antibodies, suggesting that ADCC may represent an important in vivo mechanism of action. 5 Therefore, improving the ADCC activity of full-length antibodies by immunomodulatory agents is attractive. 6 Thus, it was investigated whether costimulation of NKG2D by MICA:7D8 and ULBP2:7D8 enhanced cytotoxicity mediated by full-length antibodies. The CD38 antibody daratumumab 7 was chosen as a model, as CD38 represents a second target structure, co-expressed with CD20 on certain B-lymphoid lymphomas or leukemias. Using CD38 and CD20 double-positive Ramos cells as targets, we assessed the cytotoxic effects of combinations between either MICA:7D8 or ULBP2:7D8 at a fixed dose of 2.5 nM added to variable concentrations of daratumumab (Figure 3a ; Supplementary Figure 5) . Importantly, the presence of MICA:7D8 or ULBP2:7D8 synergistically increased the extent of daratumumab-induced ADCC. These data underline that MICA:7D8 and ULBP2:7D8 were also active in the presence of a therapeutic antibody, and signals mediated by MICA or ULBP2 and NKG2D were triggered in parallel to signals induced by the antibody Fc portion and CD16. In contrast to the two NKG2D-engaging bifunctional fusion proteins, no benefit was observed when the monoclonal CD20 antibody 7D8 was combined at a fixed dose of 2.5 nM with variable concentrations of daratumumab (Figure 3a) . Similar results were obtained when freshly isolated mantle cell lymphoma or chronic lymphocytic leukemia cells, which co-expressed CD20 and CD38, were used as target cells (Figure 3b and Supplementary Figure 5 ). These data suggest that NKG2D-directed antibody-based fusion proteins may have the potential to improve the efficacy of therapeutic full-length antibodies. NKG2D associates with the adapter molecule Dnax-activating protein 10, and unlike CD16a, not with the common Fc receptor g-chainFthereby involving different downstream signaling pathways. This may have contributed to stronger NK cell activation and accounted for the synergistic effects. 8, 9 These results were in good agreement with previous studies demonstrating that ADCC by rituximab was augmented with increasing endogenous expression levels of NKG2D ligands, and that ULBP2 fused to a full-length antibody improved the antibody's ability to lyse target cells. 10, 11 In contrast, enhancing NK cell-mediated ADCC by combinations of different antibodies may be difficult to achieve as suggested by results obtained with daratumumab and mAb 7D8, possibly because they engage the same trigger molecule. However, strategies targeting two different antigens co-expressed by tumor cells appear attractive. Therefore, combining therapeutic antibodies with bifunctional molecules such as MICA:7D8 or ULBP2:7D8 triggering cytotoxicity independently of Fc receptors may offer an attractive approach.
In summary, both MICA:7D8 and ULBP2:7D8 mediated NK cell cytotoxicity and simultaneously enhanced ADCC by fulllength antibodies. Thus, triggering natural cytotoxicity by target cell-directed NKG2D ligands may provide an innovative strategy to achieve stronger NK cell-mediated anti-lymphoma responses. Myeloid malignancies are characterized by genetic alterations either on the cytogenetic level and/or on the molecular genetic level. A large spectrum of chromosome aberrations and molecular mutations has been identified. These genetic abnormalities lead to alterations of pathways involved in cell proliferation, differentiation and apoptosis. Alterations of the RAS pathway have an important role in the pathogenesis of myeloid malignancies and occur either by activating mutations in RAS itself or by mutations in genes involved in the RAS-dependent pathways, such as FLT3, KIT or CBL. The NF1 gene encodes neurofibromin 1, a Ras-specific guanosine triphosphatase-activating protein that negatively regulates the p21ras (Ras) family of signaling proteins by accelerating GTP hydrolysis to inactive Rasguanosine diphosphate. Therefore, as NF1 is a negative regulator of RAS signaling, loss of NF1 function is likely to be functionally equivalent to an activating RAS gene mutation. Germline loss-offunction mutations of NF1 lead to neurofibromatosis type I. Carriers of the mutations develop benign neurofibromas and are predisposed not only to neuronal tumors but also to juvenile myelomonocytic leukemia, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In addition, in children suffering from chronic myelomonocytic leukemia (CMML) without germline NF1 mutations, acquired loss-of-function mutations of NF1 have been reported. The role of NF1 in adult myeloid malignancies has not been studied in detail so far. Recently, we identified cytogenetically cryptic 17q11 deletions encompassing the NF1 gene in 6 out of 37 AML cases with inv(16)(p13q22)/ t(16;16)(p13;q22). 1 17q11.2 deletions including the NF1 gene have also been detected by array comparative genomic hybridization (CGH) in 6 out of 100 consecutive de novo AML cases, 4 showing a complex aberrant karyotype and 2 an inv(16). In a study by Rücker et al., 3 in 18 out of 60 AML with complex aberrant karyotype a commonly deleted region on 17p11 -17q11 between 23.1 and 29.5 Mb including the NF1 gene was identified by using array CGH. However, only few cases and only a limited number of exons have been investigated for NF1 mutations so far.
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In order to analyze the role of NF1 in adult AML, we first evaluated NF1 gene expression in 272 AML cases using microarrays (HG-U133 Plus 2.0, Affymetrix, Santa Clara, CA, USA). These included cases with t(15;17)(q22;q12) (n ¼ 15), t(8;21)(q22;q22) (n ¼ 16), inv(16)(p13q22) (n ¼ 7), t(11q23)/ MLL-rearrangement (n ¼ 10), inv(3)(q21q26)/t(3;3)(q21;q26) (n ¼ 3), complex aberrant karyotype (n ¼ 47), normal karyotype (n ¼ 97) and with various other genetic abnormalities (n ¼ 77). The median NF1 expression intensity was 131.6 (range 35.2 -457.5). In all, 68 cases showed an expression intensity of NF1 below 98.6 (first quartile, low expression group) (Figure 1a) . In this cohort, cases with t(8;21) (n ¼ 10) or complex karyotype 
